BioSpace News Archive

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that both the United States Food and Drug Administration (FDA) and European Commission (EC) have granted Orphan Drug Designation (ODD) for PTC923 for the treatment of patients with hyperphenylalaninemia. Phenylketonuria (PKU) accounts for 98% of all hyperphenylalaninemia cases and is a metabolic condition that can lead to cognitive disabilities and seizures

Sumitovant Biopharma, Inc. today announced that its portfolio of four wholly owned subsidiary companies (Urovant, Enzyvant, Altavant and Spirovant) and Myovant Sciences (NYSE: MYOV), a publicly listed company that is majority owned by Sumitovant, achieved significant clinical and corporate milestones in the company’s fourth quarter ending on March 31, 2021.

Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that clinical data related to REL-1017, the company’s lead product candidate, will be presented in a live oral poster presentation at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

Inhalon Biopharma, a start-up immunotherapy company developing an inhaled “muco-trapping” antibody platform for treating a variety of acute respiratory infections (ARI), today announced that it has been awarded a $7 million contract by the U.S. Army Medical Research & Development Command (USAMRDC) to conduct a placebo-controlled Phase 1/2a

Orum Therapeutics, a global biotech company pioneering the development technologies for precision delivery of targeted protein degraders to treat cancer, today announced the appointment of Jae Won Kim as Chief Financial Officer.

Engine Biosciences (“Engine”) today announced the successful completion of an oversubscribed $43 million Series A funding round. Engine identifies errors in the complex genetic codes of diseases, fixing them with precise therapeutic solutions.

Biote Medical announces that CEO Terry S. Weber will present at the Jefferies Virtual Healthcare Conference on June 3 at 9:30 a.m. Eastern time in Track 1.

PSG’s Pharmacy Benefit Manager Customer Satisfaction report explores more than 40 dimensions of PBM customer satisfaction from the viewpoint of employers and health plans

Dyne Therapeutics, Inc., a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, announced that management is scheduled to participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 9:00 a.m. ET.

Verrica Pharmaceuticals Inc., a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, announced that Ted White, Verrica President and CEO, will present a business overview at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021, at 2:00 p.m. ET.